Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.
作者信息
Goldman S, Smith L, Anderson J R, Perkins S, Harrison L, Geyer M B, Gross T G, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo M S
出版信息
Leukemia. 2013 Apr;27(5):1174-7. doi: 10.1038/leu.2012.255. Epub 2012 Sep 3.
Abstract
摘要
相似文献
1
Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.
Leukemia. 2013 Apr;27(5):1174-7. doi: 10.1038/leu.2012.255. Epub 2012 Sep 3.
2
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
Br J Haematol. 2014 Nov;167(3):394-401. doi: 10.1111/bjh.13040. Epub 2014 Jul 26.
3
Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Br J Haematol. 2013 Nov;163(3):365-72. doi: 10.1111/bjh.12542. Epub 2013 Sep 6.
4
Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.
Br J Haematol. 2013 Sep;162(5):678-83. doi: 10.1111/bjh.12434. Epub 2013 Jun 27.
5
Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.
Haematologica. 2016 Oct;101(10):e411-e414. doi: 10.3324/haematol.2016.144550. Epub 2016 Jun 16.
6
Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country.
Pediatr Blood Cancer. 2011 Apr;56(4):560-7. doi: 10.1002/pbc.22905. Epub 2010 Dec 1.
7
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
Blood. 2007 Apr 1;109(7):2773-80. doi: 10.1182/blood-2006-07-036673.
8
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19.
9
Outcome of B-cell non-Hodgkin lymphoma protocol CCCG-B NHL97: a report from Chinese multi-center cooperative group.
Med Pediatr Oncol. 2002 Sep;39(3):212-4. doi: 10.1002/mpo.1374.
10
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
J Clin Oncol. 2008 May 10;26(14):2258-63. doi: 10.1200/JCO.2007.13.6929. Epub 2008 Apr 14.
引用本文的文献
1
Advancing Treatment in Pediatric Multiple Sclerosis: The Promise of B-Cell-Targeting Therapies.
Int J Mol Sci. 2025 Jun 22;26(13):5989. doi: 10.3390/ijms26135989.
2
Rituximab for children with EBV-positive Burkitt lymphoma in East Africa.
Blood Adv. 2025 May 27;9(10):2393-2401. doi: 10.1182/bloodadvances.2024015234.
3
Use of rituximab in mature, high-grade and advanced-stage pediatric B-lineage non-Hodgkin lymphomas: a systematic review, meta-analysis and the Brazilian reality.
Front Pediatr. 2025 Jan 20;13:1532274. doi: 10.3389/fped.2025.1532274. eCollection 2025.
4
Effects of different doses of rituximab on immunoglobulin levels in high-risk pediatrics with Burkitt's lymphoma.
Ann Hematol. 2024 Dec;103(12):5807-5816. doi: 10.1007/s00277-024-06059-2. Epub 2024 Nov 7.
5
binding domain mutations are bad news in Burkitt lymphoma.
Haematologica. 2024 Sep 1;109(9):2775-2777. doi: 10.3324/haematol.2024.285213.
6
Effect of rituximab on immune status in children with aggressive mature B-cell lymphoma/leukemia-a prospective study from CCCG-BNHL-2015.
Heliyon. 2024 Mar 5;10(5):e27305. doi: 10.1016/j.heliyon.2024.e27305. eCollection 2024 Mar 15.
7
BET bromodomain inhibitors PFI-1 and CPI-203 suppress the development of follicular lymphoma via regulating Wnt/β-catenin signaling.
Heliyon. 2024 Feb 27;10(5):e27149. doi: 10.1016/j.heliyon.2024.e27149. eCollection 2024 Mar 15.
8
DNA binding domain mutational status and rituximabbased treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.
Haematologica. 2024 Sep 1;109(9):3031-3036. doi: 10.3324/haematol.2023.284868.
9
Modern treatment strategies in pediatric oncology and hematology.
Discov Oncol. 2023 Jun 14;14(1):98. doi: 10.1007/s12672-023-00658-7.
10
Pediatric Autologous Hematopoietic Stem Cell Transplantation: Safety, Efficacy, and Patient Outcomes. Literature Review.
Pediatric Health Med Ther. 2023 May 31;14:197-215. doi: 10.2147/PHMT.S366636. eCollection 2023.
本文引用的文献
1
Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study.
J Clin Oncol. 2012 Feb 1;30(4):387-93. doi: 10.1200/JCO.2010.33.3369. Epub 2012 Jan 3.
2
Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report.
Br J Haematol. 2011 Jun;153(6):758-63. doi: 10.1111/j.1365-2141.2011.08681.x. Epub 2011 Apr 18.
3
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Blood. 2010 Sep 23;116(12):2040-5. doi: 10.1182/blood-2010-03-276246. Epub 2010 Jun 14.
4
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
J Clin Oncol. 2010 Jul 1;28(19):3115-21. doi: 10.1200/JCO.2009.26.6791. Epub 2010 Jun 1.
5
Rituximab in high-grade lymphoma.
Semin Hematol. 2010 Apr;47(2):148-55. doi: 10.1053/j.seminhematol.2010.01.008.
6
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Blood. 2009 May 14;113(20):4834-40. doi: 10.1182/blood-2008-10-186999. Epub 2009 Mar 5.
7
A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Pediatr Blood Cancer. 2009 Feb;52(2):177-81. doi: 10.1002/pbc.21753.
8
The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
Ann Hematol. 2008 Jun;87(6):481-5. doi: 10.1007/s00277-008-0454-3. Epub 2008 Feb 26.
9
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.
Blood. 2007 Apr 1;109(7):2736-43. doi: 10.1182/blood-2006-07-036665.
10
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
Blood. 2007 Apr 1;109(7):2773-80. doi: 10.1182/blood-2006-07-036673.
Zotero 插件